Trichostatin A, a HDAC inhibitor, was predicted to be potentially efficient in all soft tissue sarcoma subtypes, while another HDAC inhibitor, Vorinostat, was identified for UPS and ULMS. Here, HDAC9 is linked to soft tissue sarcoma.